Symbols

ALNY

Alnylam Pharmaceuticals·NASDAQ

--(--)

ALNY fundamentals

ALNY Q4 2025 Earnings

Alnylam Pharmaceuticals (ALNY) released its earnings on Feb 12, 2026: revenue was 1.10B (YoY +84.95%), missed estimates; EPS was 0.82 (YoY +226.15%), missed estimates.

Revenue / YoY

1.10B

+84.95%

EPS / YoY

0.82

+226.15%

Report date

Feb 12, 2026

ALNY Earnings Call Summary for Q4,2025

Record Revenue Growth: 2025 net product revenues reached $2.99 billion (+81% YoY), driven by TTR franchise expansion.
GAAP Profitability Achieved: Full-year non-GAAP operating income of $850 million, marking a new era of sustained profitability.
2030 Ambitious Goals: 25% CAGR, 30% operating margin, and TTR market leadership by 2030.
Pipeline Momentum: 40+ clinical programs, including Phase III studies for zilebesiran and nucresiran, with siRELIS manufacturing platform to reduce COGS.
AMVUTTRA Dominance: 90% U.S. first-line coverage, near-parity new patient starts vs. tafamidis, and 95% TTR knockdown profile.

Earnings

EPS

Revenue

Revenue & Expenses

ALNY has released its 2025 Q4 earnings report, with revenue of 1.10B, reflecting a YoY change of 84.95%, and net profit of 186.42M, showing a YoY change of 322.56%. The Sankey diagram below clearly presents ALNY's revenue sources and cost distribution.

Key Indicators

Alnylam Pharmaceuticals (ALNY) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Alnylam Pharmaceuticals (ALNY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Alnylam Pharmaceuticals (ALNY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Alnylam Pharmaceuticals (ALNY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown